Bordetella pertussis component Vaccine Adjuvant |
|
Vaxjo ID |
32 |
|
Vaccine Adjuvant Name |
Bordetella pertussis component Vaccine Adjuvant |
|
Adjuvant VO ID |
VO_0000193
|
|
Description |
Bordetella pertussis, is an organism that acts as an adjuvant (Kind, 1957) and possesses the ability to induce splenomegaly (Morse, 1965), in being able to sensitise susceptible strains of mice to endotoxin (Howard, 1968) and to histamine (Adlam et al1965) (Adlam and Scott, 1973). |
|
Stage of Development |
Licensed |
|
Location Licensed |
USA |
|
Host Species for Testing |
Human |
|
Components |
Bordetella pertussis vaccine (PV) or components derived from phase I B. pertussis organisms (Athanassiades, 1977). |
|
Function |
When Bordetella pertussis vaccine (PV) adjuvant is injected into experimental animals, it induces a variety of profound functional and morphological alterations in the cells and tissues comprising the lymphomyeloid complex (Athanassiades, 1977). |
|
Safety |
At present, there is a need to discover substances that can be safely employed clinically as adjuvants to increase the weak antigenicity of tumor and viral antigens, especially with regard to enhancing the cell-mediated immune response of the host. Not only is PV a relatively safe vaccine, but there is also increasing evidence that it is among the most effective of all adjuvants (Athanassiades, 1977). |
| Related Vaccine(s) |
|
| References |
Adlam and Scott, 1973: Adlam C, Scott MT. Lympho-reticular stimulatory properties of Corynebacterium parvum and related bacteria. Journal of medical microbiology. 1973; 6(3); 261-274. [PubMed: 4726332].
Athanassiades, 1977: Athanassiades TJ. Adjuvant effect of Bordetella pertussis vaccine to sheep erythrocytes in mice: enhancement of cell-mediated immunity by subcutaneous administration of adjuvant and antigen. Infection and immunity. 1977; 18(2); 416-423. [PubMed: 924677].
|
